CTC
CRDL

Central Trust Company’s Cardiol Therapeutics CRDL Stock Holding History

Central Trust Company’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-400
Closed -$792 – 1443
2024
Q3 		$792 Buy
+400
New +$830 ﹤0.01% 1337

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Atria Investments Charlotte, North Carolina $8.94B AUM 20.84% 1-Year Est. Return

Central Trust Company's CRDL Position: Q4 2024 in Review

Central Trust Company sold out of Cardiol Therapeutics (CRDL) in Q4 2024, closing a stake of 400 shares — an estimated $792 sold.

Central Trust Company first reported a position in CRDL in Q3 2024 and held it in 1 quarter. The position peaked at $792 in Q3 2024. 43 funds tracked by Wall St. Rank hold CRDL as of Q4 2024.

  • Central Trust Company reported no remaining Cardiol Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Central Trust Company sold 400 Cardiol Therapeutics shares in Q4 2024, an estimated $792.
  • Central Trust Company first reported a position in Cardiol Therapeutics in Q3 2024 and held it in 1 quarter.
  • Central Trust Company's Cardiol Therapeutics position peaked at $792 in Q3 2024.
  • 43 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q4 2024.

Based on Central Trust Company's 13F filing for Q4 2024, filed 24 Jan 2025.